Cargando…

Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages

OBJECTIVE: Although pancreatic ductal adenocarcinoma is considered a rapidly progressive disease, mathematical models estimate that it takes many years for an initiating pancreatic cancer cell to grow into an advanced stage cancer. In order to estimate the time it takes for a pancreatic cancer to pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Jun, Blackford, Amanda L, dal Molin, Marco, Wolfgang, Christopher L, Goggins, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Pancreas
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520782/ https://www.ncbi.nlm.nih.gov/pubmed/25636698 http://dx.doi.org/10.1136/gutjnl-2014-308653

Ejemplares similares

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
por: Raj, Deepak, et al.
Publicado: (2019)

Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma
por: Nywening, Timothy M, et al.
Publicado: (2018)

Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications
por: Luchini, Claudio, et al.
Publicado: (2021)

Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma
por: Alonso-Nocelo, Marta, et al.
Publicado: (2023)

Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase
por: Reinert, Christian Philipp, et al.
Publicado: (2020)

Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma
por: Dal Molin, Marco, et al.
Publicado: (2016)

Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making programme using decision tables
por: Scholten, Lianne, et al.
Publicado: (2020)

Non-contrast-enhanced CT texture analysis of primary and metastatic pancreatic ductal adenocarcinomas: value in assessment of histopathological grade and differences between primary and metastatic lesions
por: Janisch, Michael, et al.
Publicado: (2022)

Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case–control study
por: Tan, Pui San, et al.
Publicado: (2023)

Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours
por: Huang, Hsi-Chien, et al.
Publicado: (2022)

Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms
por: Yu, Jun, et al.
Publicado: (2017)

Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression
por: Ruivo, Carolina F, et al.
Publicado: (2022)

Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer
por: Mahajan, Ujjwal M, et al.
Publicado: (2016)

Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment
por: Wang, Liwen, et al.
Publicado: (2023)

Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer
por: Goehrig, Delphine, et al.
Publicado: (2019)

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
por: Hackeng, Wenzel M, et al.
Publicado: (2022)

GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
por: Martinelli, Paola, et al.
Publicado: (2017)

Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours
por: Young, Kate, et al.
Publicado: (2021)

Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We Include Grade in AJCC Staging?
por: Wasif, Nabil, et al.
Publicado: (2010)

Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system
por: Hong, Xiafei, et al.
Publicado: (2020)

Cost–effectiveness of pancreatic cancer screening: Time for a more tailored approach
por: Archibugi, Livia, et al.
Publicado: (2023)

High signal intensity on diffusion-weighted magnetic resonance images is a useful finding for detecting early-stage pancreatic cancer
por: Kurita, Akira, et al.
Publicado: (2021)

Time trends in incidence and prevalence of chronic pancreatitis: A 25‐year population‐based nationwide study
por: Olesen, Søren S., et al.
Publicado: (2021)

Prediction of infected pancreatic necrosis in acute necrotizing pancreatitis by the modified pancreatitis activity scoring system
por: Mao, Wenjian, et al.
Publicado: (2022)

Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas
por: Handra-Luca, A, et al.
Publicado: (2011)

The Impact of COVID-19 on Time-to-treatment in Pancreatic Adenocarcinoma: A Single Institutional Experience
por: Sugumar, Kavin, et al.
Publicado: (2021)

Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling
por: Hohwieler, Meike, et al.
Publicado: (2017)

Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model
por: Kumar, Sumit, et al.
Publicado: (2022)

Post‐pancreatitis diabetes mellitus is common in chronic pancreatitis and is associated with adverse outcomes
por: Dugic, Ana, et al.
Publicado: (2022)

Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype
por: Liffers, Sven-Thorsten, et al.
Publicado: (2023)

The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program
por: Levink, Iris J. M., et al.
Publicado: (2023)

Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis
por: de la Iglesia-García, Daniel, et al.
Publicado: (2017)

Targeting mTOR dependency in pancreatic cancer
por: Morran, Douglas C, et al.
Publicado: (2014)

Long-term yield of pancreatic cancer surveillance in high-risk individuals
por: Overbeek, Kasper A, et al.
Publicado: (2022)

Relationship between pancreatic parenchyma loss and early postoperative hyperglycemia in patients with benign pancreatic diseases
por: Wen, Kan, et al.
Publicado: (2021)

Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer
por: Gaiser, Rogier Aäron, et al.
Publicado: (2019)

Quantitative MRI of chronic pancreatitis: results from a multi-institutional prospective study, magnetic resonance imaging as a non-invasive method for assessment of pancreatic fibrosis (MINIMAP)
por: Tirkes, Temel, et al.
Publicado: (2022)

Pancreatic enzyme treatment in chronic pancreatitis: Quality of management and adherence to guidelines–A cross‐sectional observational study
por: Erchinger, Friedemann, et al.
Publicado: (2022)

Quality of life after endoscopic procedures for chronic pancreatitis: A multicentre study
por: Parhiala, Mikael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e7r5jd03acj8na0bdp5orvabp9